Ani-survivin DNAzymes Inhibit Cell Proliferation and Migration in Breast Cancer Cell Line MCF-7

  • Zhang, Min (Beihua University) ;
  • Sun, Yi-Fu (Norman Bethune College of Medicine, Jilin University) ;
  • Luo, Su (Beihua University)
  • Published : 2012.12.31


Survivin, a new member of the inhibitor of apoptosis protein (IAP) family, both inhibits apoptosis and regulates the cell cycle. It is overexpressed in breast tumor tissues. In this study, we designed two survivin specific DNAzymes (DRz1 and DRz2) targeting survivin mRNA. The results showed that DRz1 could decrease the expression of survivin by nearly 60%. Furthermore, DRz1 significantly inhibited cell proliferation, induced apoptosis and inhibited migration in MCF-7 cells. In addition, down-regulation of survivin expression was associated with increased caspase-3 and -9 activities in MCF-7 cells after 24 h transfection. In our experiments, the efficacy of DRz1 to influence survivin levels and associated effects were better than DRz2. Survivin-DRz1 might have anti-tumorigenic activity and may potentially provide the basis for a novel therapeutic intervention in breast cancer treatment.


DNAzymes;proliferation;apoptosis;survivin;breast cancer


  1. Xu C, Yamamoto-Ibusuki M, Yamamoto Y, et al (2012). High survivin mRNA expression is a predictor of poor prognosis in breast cancer: a comparative study at the mRNA and protein level. Breast Cancer.
  2. Yakirevich E, Samkari A, Holloway MP, et al (2012).Total Survivin and acetylated Survivin correlate with distinct molecular subtypes of breast cancer. Hum Pathol, 43, 865-73.
  3. Yuan SF, Zhu LJ, Zheng WE, et al (2012). Expression of betatubulin III and survivin in advance stage breast cancer correlates with chemotherapeutic effects of docetaxel. Asian Pac J Cancer Prev, 13, 361-5.
  4. Zhou H, Tang Y, Liang X, et al (2009). RNAi targeting urokinasetype plasminogen activator receptor inhibits metastasis and progression of oral squamous cell carcinoma in vivo. Int J Cancer, 125, 453-62.
  5. Zhou H, Tang Y, Liang X, et al (2009). RNAi targeting urokinasetype plasminogen activator receptor inhibits metastasis and progression of oral squamous cell carcinoma in vivo. Int J Cancer, 125, 453-62.
  6. N, Haywood P, Flint P, et al (2006). Survivin expression in situ and invasive breast cancer relates to COX-2 expression and DCIS recurrence. Br J Cancer, 94, 253-8.
  7. Baxi SM, Tan W, Murphy ST, et al (2012). Targeting 3-phosphoinoside-dependent kinase-1 to inhibit insulin-like growth factor-I induced AKT and p70 S6 kinase activation in breast cancer cells. PLoS One, 7, e48402.
  8. Gritsko T, Williams A, Turkson J, et al (2006).Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res, 12, 11-9.
  9. He J, Zhang D, Wang Q, et al (2011). A novel strategy of chemical modification for rate enhancement of 10-23 DNAzyme: a combination of A9 position and 8-aza-7-deaza-2'-deoxyadenosine analogs. Org Biomol Chem, 9, 5728-36.
  10. McManus SA, Li Y (2010). The structural diversity of deoxyribozymes. Molecules, 15, 6269-84.
  11. Montazeri Aliabadi H, Landry B, Mahdipoor P, et al (2012). Induction of apoptosis by survivin silencing through siRNA delivery in a human breast cancer cell line. Mol Pharm, 8, 1821-30.
  12. Mosmann T (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods, 65, 55-63.
  13. Schlosser K, Li Y (2009). Biologically inspired synthetic enzymes made from DNA. Chem Biol, 16, 311-22.
  14. Verma N, Tripathi SK, Chaudhury I, et al (2010). iNOStargeted 10-23 DNAzyme reduces LPS- induced systemic inflammation and mortality in mice. Shock, 33, 493-9.
  15. Wang F, Elbaz J, Orbach R, et al (2011). Amplified analysis of DNA by the autonomous assembly of polymers consisting of DNAzyme wires. J Am Chem Soc, 133, 17149-51.
  16. Wang TH, Li WT, Yu SH, Au LC (2008). The use of 10-23 DNAzyme to selectively destroy the allele of mRNA with a unique purine-pyrimidine dinucleotide. Oligonucleotides, 18: 295-299.

Cited by

  1. Chimeric nucleolin aptamer with survivin DNAzyme for cancer cell targeted delivery vol.51, pp.32, 2015,
  2. Biodegradable, multifunctional DNAzyme nanoflowers for enhanced cancer therapy vol.9, pp.3, 2017,
  3. A NIR-light activated nanoplatform for sensitizing triple negative breast cancer against therapeutic resistance to enhance the treatment effect pp.2050-7518, 2018,